

Performance Against Delivery Benchmark

Count	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure
1	18/LO/1311	248599	GR40398 EFFICACY AND SAFETY OF RO6867461 IN DMO PATIENTS (RHINE) v1	Number Agreed	5	5	Date Agreed	30/11/2019	2	22/08/2019	2	Recruitment Finished
2	18/WS/0137	247036	VISION Study of 177Lu-PSMA-617 in the treatment of PSMA-Positive mCRPC	Number Agreed	6	6	Date Agreed	22/08/2019	3	29/08/2019	3	Recruitment Finished
3	19/EM/0003	251874	Phase 3 Study of Edasalonexent in Duchenne Muscular Dystrophy	Number Agreed	2	2	Date Agreed	30/06/2020	4	03/09/2019	4	Recruitment Finished
4	18/SC/0342	247085	Phase III Trial of AMT-061 in adults with haemophilia B	Number Agreed	1	1	Date Agreed	30/09/2019	0	03/09/2019	0	Recruitment Finished
5	18/WS/0172	251636	1011712	Number Agreed	5	5	Date Agreed	30/08/2019	0	04/09/2019	0	Withdrawn By Sponsor
6	16/LO/0543	198734	GMP Drink for PKU Study	Number Agreed	1	1	Date Agreed	31/12/2019	3	30/09/2019	3	Recruitment Finished
7	18/WM/0190	240027	Combi-Aplus: Dabrafenib + Trametinib in BRAF+ve Melanoma	Number Agreed	8	8	Date Agreed	29/08/2019	9	26/09/2019	9	Recruitment Finished
8	17/NW/0022	219189	Post-Authorization Study of HyQvia in Pediatric PIDD subjects	Number Agreed	2	2	Date Agreed	31/12/2019	5	22/10/2019	5	Recruitment Finished
9	17/YH/0392	230501	BI 1467335 in patients with diabetic retinopathy.	Number Agreed	2	2	Date Agreed	31/10/2019	2	31/10/2019	2	Recruitment Finished
10	19/EM/0047	257111	GR40306 (TENAYA): A study of faricimab in nAMD	Number Agreed	4	4	Date Agreed	31/12/2019	4	31/10/2019	4	Recruitment Finished
11	19/YH/0067	254066	CANOPY-1	Number Agreed	3	3	Date Agreed	21/10/2022	0	05/12/2019	0	Recruitment Finished
12	19/NW/0482	269475	Kepler	Number Agreed	2	2	Date Agreed	30/03/2020	2	19/12/2019	2	Recruitment Finished
13	18/LO/0723	244615	RPC01-3203:study of Ozanimod as Maintenance therapy for Crohns Disease	Number Agreed	1	1	Date Agreed	28/02/2020	0	22/08/2019	0	Withdrawn By Host
14	18/LO/0722	238635	A Phase 3 study of Ozanimod as induction therapy for Crohn?s Disease	Number Agreed	1	1	Date Agreed	01/09/2020	0	23/08/2019	0	Withdrawn By Host
15	18/LO/1223	244752	RPC01-3204: Open Label Extension study of Ozanimod for Crohn?s Disease	Number Agreed	1	1	Date Agreed	30/11/2020	0	23/08/2019	0	Withdrawn By Host
16	18/EE/0378	248600	Conbercept in Neovascular Age-related Macular Degeneration	Number Agreed	5	5	Date Agreed	31/05/2020	11	18/12/2019	11	Recruitment Finished
17	18/LO/1450	248611	Marigold Study 4407/0001 Marinus	Number Agreed	4	4	Date Agreed	31/12/2019	5	31/12/2019	5	Recruitment Finished
18	17/SW/0174	228278	A Phase 2 Clinical Trial in Patients with AML version amend 4	Number Agreed	1	1	Date Agreed	30/07/2021	1	06/01/2020	1	Recruitment Finished
19	17/LO/1476	224732	A phase 2a Study in Adult Volunteers with Sickle Cell Anaemia - 001	Number Agreed	2	2	Date Agreed	17/01/2020	3	17/01/2020	3	Recruitment Finished

Performance Against Delivery Benchmark

Count	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure
20	16/LO/0814	199311	CHIL4593 - Sarilumab, administered with subcutaneous (SC) injection, in patients aged 2 to 17, with polyarticular-course juvenile idiopathic arthritis (pcJIA) followed by an extension phase	Number Agreed	1	1	Date Agreed	30/06/2020	0	27/01/2020	0	Recruitment Finished
21	16/LO/1960	199019	CHIL4595	Number Agreed	1	1	Date Agreed	30/09/2019	0	27/01/2020	0	Recruitment Finished
22	19/YH/0099	257815	LAT8881 in Neuropathic Pain	Number Agreed	11	11	Date Agreed	31/03/2020	7	31/01/2020	7	Recruitment Finished
23	18/LO/1187	240011	ATHENA - a first line ovarian cancer maintenance trial.	Number Agreed	4	4	Date Agreed	30/04/2020	3	31/01/2020	3	Recruitment Finished
24	19/SC/0113	241916	Idera 2125-MEL-301	Number Agreed	2	2	Date Agreed	31/12/2019	1	05/02/2020	1	Recruitment Finished
25	17/EM/0152	216307	Post-transplant Gilteritinib maintenance in acute myeloid leukaemia	Number Agreed	5	5	Date Agreed	15/02/2020	7	15/02/2020	7	Recruitment Finished
26	19/NI/0110	260538	EluNIR HBR study	Number Agreed	8	8	Date Agreed	31/07/2020	5	28/02/2020	5	Recruitment Finished
27	18/NW/0694	248847	Derby - Geographic Atrophy secondary to AMD	Number Agreed	2	2	Date Agreed	31/03/2020	1	13/03/2020	1	Recruitment Finished
28	16/EE/0446	214004	Niraparib in men with mCRPC and DNA repair anomalies	Number Agreed	2	2	Date Agreed	23/07/2020	3	22/05/2020	5	Recruitment Finished
29	15/SW/0089	164916	GAST 3847	Number Agreed	20	20	Date Agreed	15/04/2019	54	19/07/2019	55	Recruitment Finished